Understand the source comparison
Does TB-4 Help Hair Growth Research: Delivery Method Comparison
Choosing between topical, subcutaneous, and intradermal delivery of TB-4 for hair growth research involves trade-offs in bioavailability, patient compliance, and targeted follicular concentration. Each method has been explored in regenerative medicine contexts
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Choosing between topical, subcutaneous, and intradermal delivery of TB-4 for hair growth research involves trade-offs in bioavailability, patient compliance, and targeted follicular concentration. Each method has been explored in regenerative medicine contexts, but follicle-specific optimization is incomplete.
- Topical Solution (0.01–0.1%)
- 5–12% transdermal
- Twice daily
- Variable. Depends on formulation vehicle and stratum corneum integrity
- Minimal
- Best for patients unwilling to inject but requires penetration enhancers (DMSO, liposomes) to reach bulb depth
- Subcutaneous Injection (2–10mg)
- 85–95%
- 2–3× weekly
- Systemic distribution. No direct follicle targeting
- Moderate to high
- Delivers consistent plasma levels but lacks scalp-specific concentration. May benefit overall tissue regeneration
- Intradermal Microneedling + Topical (0.05%)
- 20–35% enhanced by micropuncture
- Weekly with microneedling
- High. Micropunctures bypass stratum corneum
- Low
- Emerging approach. Combines mechanical stimulation with peptide delivery, shows promise in small trials
- The biggest gap in current TB-4 hair growth research is the absence of dose-response studies establishing the minimum effective concentration at the follicle bulb. Topical formulations struggle with molecular weight (approximately 5 kDa for TB-4) and hydrophilicity, both of which limit passive diffusion through the lipid-rich stratum corneum. Researchers have experimented with liposomal encapsulation and penetration-enhancing solvents like dimethyl sulfoxide (DMSO), but these formulations are not yet commercially standardized.
- Subcutaneous administration achieves reliable plasma levels but distributes TB-4 systemically rather than concentrating it in the scalp. This approach may benefit patients using TB-4 for broader regenerative purposes. Tissue repair, tendon healing, or cardiovascular applications. Where hair regrowth is a secondary outcome. Intradermal delivery via microneedling offers a middle path: mechanical punctures create temporary channels that allow peptide penetration while also triggering localized wound healing responses that may synergize with TB-4's regenerative effects.